↓ Skip to main content

Phosphodiesterases as Drug Targets

Overview of attention for book
Cover of 'Phosphodiesterases as Drug Targets'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Phosphodiesterase Inhibitors: History of Pharmacology
  3. Altmetric Badge
    Chapter 2 Phosphodiesterase Inhibitors: Factors That Influence Potency, Selectivity, and Action
  4. Altmetric Badge
    Chapter 3 Pharmacology, clinical efficacy, and tolerability of phosphodiesterase-4 inhibitors: impact of human pharmacokinetics.
  5. Altmetric Badge
    Chapter 4 Structural Insight into the Substrate Specificity of Phosphodiesterases
  6. Altmetric Badge
    Chapter 5 A Fission Yeast-Based Platform for Phosphodiesterase Inhibitor HTSs and Analyses of Phosphodiesterase Activity
  7. Altmetric Badge
    Chapter 6 The GAF-Tandem Domain of Phosphodiesterase 5 as a Potential Drug Target
  8. Altmetric Badge
    Chapter 7 Small Molecule Allosteric Modulators of Phosphodiesterase 4
  9. Altmetric Badge
    Chapter 8 Regulation of Endothelial Barrier Function by Cyclic Nucleotides: The Role of Phosphodiesterases
  10. Altmetric Badge
    Chapter 9 Phosphodiesterases as Targets for Intermittent Claudication
  11. Altmetric Badge
    Chapter 10 Phosphodiesterase Inhibition in Heart Failure
  12. Altmetric Badge
    Chapter 11 Phosphodiesterases: Emerging Therapeutic Targets for Neonatal Pulmonary Hypertension
  13. Altmetric Badge
    Chapter 12 Role of Phosphodiesterases in Adult-Onset Pulmonary Arterial Hypertension
  14. Altmetric Badge
    Chapter 13 Treatment of Erectile Dysfunction and Lower Urinary Tract Symptoms by Phosphodiesterase Inhibitors
  15. Altmetric Badge
    Chapter 14 Evaluation of the Therapeutic Utility of Phosphodiesterase 5A Inhibition in the mdx Mouse Model of Duchenne Muscular Dystrophy
  16. Altmetric Badge
    Chapter 15 Phosphodiesterases as Targets for Modulating T-Cell Responses
  17. Altmetric Badge
    Chapter 16 Cyclic Nucleotides and Phosphodiesterases in Monocytic Differentiation
  18. Altmetric Badge
    Chapter 17 Phosphodiesterase Inhibitors in the Treatment of Inflammatory Diseases
  19. Altmetric Badge
    Chapter 18 Harnessing the Clinical Efficacy of Phosphodiesterase 4 Inhibitors in Inflammatory Lung Diseases: Dual-Selective Phosphodiesterase Inhibitors and Novel Combination Therapies
  20. Altmetric Badge
    Chapter 19 Phosphodiesterases in the Central Nervous System: Implications in Mood and Cognitive Disorders
  21. Altmetric Badge
    Chapter 20 Therapeutic Potential of Phosphodiesterase Inhibitors in Parasitic Diseases
Attention for Chapter 11: Phosphodiesterases: Emerging Therapeutic Targets for Neonatal Pulmonary Hypertension
Altmetric Badge

Citations

dimensions_citation
28 Dimensions

Readers on

mendeley
35 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Phosphodiesterases: Emerging Therapeutic Targets for Neonatal Pulmonary Hypertension
Chapter number 11
Book title
Phosphodiesterases as Drug Targets
Published in
Handbook of experimental pharmacology, January 2011
DOI 10.1007/978-3-642-17969-3_11
Pubmed ID
Book ISBNs
978-3-64-217968-6, 978-3-64-217969-3
Authors

Kathryn N. Farrow, Robin H. Steinhorn, Farrow, Kathryn N., Steinhorn, Robin H.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 35 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 7 20%
Researcher 6 17%
Other 4 11%
Student > Bachelor 3 9%
Student > Postgraduate 3 9%
Other 6 17%
Unknown 6 17%
Readers by discipline Count As %
Medicine and Dentistry 15 43%
Nursing and Health Professions 4 11%
Agricultural and Biological Sciences 2 6%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Biochemistry, Genetics and Molecular Biology 1 3%
Other 3 9%
Unknown 9 26%